Tumour lysis syndrome: new therapeutic strategies and classification
Tóm tắt
Tumour lysis syndrome (TLS) describes the metabolic derangements that occur with tumour breakdown following the initiation of cytotoxic therapy. TLS results from the rapid destruction of malignant cells and the abrupt release of intracellular ions, nucleic acids, proteins and their metabolites into the extracellular space. These metabolites can overwhelm the body's normal homeostatic mechanisms and cause hyperuricaemia, hyperkalaemia, hyperphosphaetemia, hypocalcaemia and uraemia. TLS can lead to acute renal failure and can be life‐threatening. Early recognition of patients at risk and initiation of therapy for TLS is essential. There is a high incidence of TLS in tumours with high proliferative rates and tumour burden such as acute lymphoblastic leukaemia and Burkitt's lymphoma. The mainstays of TLS prophylaxis and treatment include aggressive hydration and diuresis, control of hyperuricaemia with allopurinol prophylaxis and rasburicase treatment, and vigilant monitoring of electrolyte abnormalities. Urine alkalinization remains controversial. Unfortunately, there have been few comprehensive reviews on this important subject. In this review, we describe the incidence, pathophysiological mechanisms of TLS and risk factors for its development. We summarise recent advances in the management of TLS and provide a new classification system and recommendations for prophylaxis and/or treatment based on this classification scheme.
Từ khóa
Tài liệu tham khảo
Bishop M.R., 2000, Clinical Oncology, 750
Brogard J.M., 1972, Enzymatic uricolysis: a study of the effect of a fungal urate‐oxydase, Revue Europeenne D Etudes Cliniques et Biologiques, 17, 890
Hande K.R., 1981, Postchemotherapy purine excretion in lymphoma patients receiving allopurinol, Cancer Research, 41, 2273
Legoux R., 1992, Cloning and expression in Escherichia coli of the gene encoding Aspergillus flavus urate oxidase, The Journal of Biological Chemistry, 267, 8565, 10.1016/S0021-9258(18)42480-5
O'Regan S., 1977, Electrolyte and acid‐base disturbances in the management of leukemia, Blood, 49, 345, 10.1182/blood.V49.3.345.345
Silverman P., 1989, Metabolic emergencies in clinical oncology, Seminars in Oncology, 16, 504
Tannock I., 1978, Cell kinetics and chemotherapy: a critical review, Cancer Treatment Reports, 62, 1117
Ten Harkel A.D., 1998, Alkalinization and the tumor lysis syndrome, Medical and Pediatric Oncology, 31, 27, 10.1002/(SICI)1096-911X(199807)31:1<27::AID-MPO6>3.0.CO;2-1